CG Oncology, Inc.
CG Oncology, Inc. (Nasdaq: CGON) is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. The candidate is designed to kill cancer cells through selective replication and stimulate an anti-tumor immune response. Its… From the company’s description.
Over the twelve months to Sep 30, 2026, CG Oncology, Inc. reported revenue of $6.17M, up 183.6% from a year earlier, and a net loss of $237.46M. Operations used $187.28M in cash. In fiscal 2025, it reported revenue of $4.04M, up 254.7% from fiscal 2024, and a net loss of $161.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CG Oncology, Inc. does
In the company’s own words
CG Oncology, Inc. (Nasdaq: CGON) is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. The candidate is designed to kill cancer cells through selective replication and stimulate an anti-tumor immune response. Its clinical program focuses on non-muscle invasive bladder cancer (NMIBC), including high-risk disease unresponsive to Bacillus Calmette-Guérin (BCG), as well as intermediate-risk, BCG-naïve and BCG-exposed populations. Cretostimogene is administered into the bladder, and the company is evaluating it as a monotherapy and in combination with other treatments, including pembrolizumab and gemcitabine. Its development program includes Phase 3 trials BOND-003 in high-risk BCG-unresponsive NMIBC and PIVOT-006 in intermediate-risk NMIBC, alongside Phase 2 cohorts. The company initiated a U.S. biologics license application for its initial indication in the fourth quarter of 2025. As of January 30, 2026, cretostimogene had been administered to more than 740 patients in clinical trials.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- DALLAS, TX
- Fiscal year end
- December
- CIK
- 1991792
- SIC
- 2836
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CG Oncology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CG Oncology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CG Oncology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CG Oncology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CG Oncology, Inc.'s last four quarterly filings that the numbers alone won't show?”